MarketBeat
18 Oct 2025, 16:04 UTC · 49w ago
Verdict
Headline takes no side. We score JNJ +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Johnson & Johnson is speculated to be pursuing a complete acquisition of its partner, Protagonist Therapeutics (PTGX).
More positive than 99% of claims this week
Johnson & Johnson plans to separate its Orthopedics business, which generated approximately $9.2 billion in 2024 sales.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 87% of claims this week
The drug icotrokinra, developed with Protagonist, has been submitted to the FDA for plaque psoriasis and showed superiority to deucravacitinib in trials.
More positive than 79% of claims this week
Johnson & Johnson generated approximately $14 billion in free cash flow in the first three quarters of 2025.
So whatStrong cash flow provides the liquidity needed for M&A and ensures the sustainability of its dividend payments.
More positive than 66% of claims this week
The company is utilizing a disciplined M&A strategy to offset the upcoming patent cliff for its multi-billion-dollar drug, Stelara.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The article highly praises the company's disciplined M&A strategy, strong cash flow, and commitment to shareholder dividends.
More positive than 76% of ticker scores this week
The company is described as a partner with highly promising, clinically validated assets that are targets for acquisition.
Near neutral — 92% of ticker scores this week are stronger
Mentioned only as part of a past spinoff process without specific positive or negative current outlook.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
1h ago
More positive than 56% of relationship scores this week
[b_to_a] Kenvue was spun off from Johnson & Johnson's consumer health business in 2023.
More positive than 3% of relationship scores this week
[a_to_b] There is market speculation regarding a complete acquisition of Protagonist Therapeutics by Johnson & Johnson.
+40.4%
Price agrees with the score
$271.22 vs $193.22 close before publication (Oct 17) · not market-adjusted
JNJ chart →
